PTG-200

November 11, 2019November 11, 2019

1st Patient Dosed in Phase 2 Trial of Investigational PTG-200 for Crohn’s Disease, Protagonist Announces

News

The first patient has been dosed in Protagonist Therapeutics’ Phase 2 clinical trial of PTG-200 for the treatment of moderate to severe Crohn’s disease, the company announced. Still recruiting at ... Read more

December 5, 2018December 5, 2018

Potential IBD Therapy PTG-200 Safe, Well-tolerated in Healthy Volunteers, Phase 1 Results Show

News

PTG-200, being developed by Protagonist Therapeutics in collaboration with Janssen Biotech for the treatment of moderate and severe Crohn’s disease, was found safe and well-tolerated in healthy volunteers, according to top-line results of ... Read more

January 12, 2018

Protagonist Obtains Third Patent for Therapy Targeting a Bowel Disease-related Protein

News

Protagonist Therapeutics has obtained a U.S. patent for an inflammatory bowel disease treatment that is in clinical trials. PTG-100 inhibits a protein known as alpha-4-beta-7 integrin that is associated with IBDs. Scientists consider it one ... Read more

June 1, 2017

Janssen and Protagonist to Develop, Market PTG-200 for the Treatment of IBD

News

Janssen Biotech and Protagonist Therapeutics are partnering to develop, manufacture, and market PTG-200 as a treatment for Crohn’s disease and ulcerative colitis (UC). PTG-200 is a potential first-in-class oral IL-23R antagonist ... Read more

May 17, 2017May 17, 2017

New Patent Cover IL-23R Orally Stable Peptide Inhibitors Including Protagonist’s PTG-200 to Treat IBD

News

Protagonist Therapeutics has secured a patent covering orally stable peptide inhibitors of the interleukin-23 receptor (IL-23R), including its lead candidate drug PTG-200. The patent protects PTG-200’s formulation as well the use of this ... Read more

May 4, 2017

Protagonist to Present Preclinical Findings on PTG-200 for Crohn’s Disease at Conference

News

Protagonist Therapeutics will present preclinical research data on its investigational drug PTG-200 as a potential treatment for Crohn’s disease. The findings will be presented May 6 at the Digestive Disease Week conference ... Read more